Search
pivmecillinam (Selexid, Penomax, Coactabs)
Indications:
- treatment of urinary tract infection (FDA-approved April 2024) [2]
- paratyphoid fever
- shigellosis
Contraindications:
- carnitine deficiency
- other forms of inborn errors of metabolism
- methymalonic acidururia
- propionic aciduria
Dosage:
- 185 mg PO TID for 3 to 7 days
Tablets: 185 mg
Pharmacokinetics:
- pro-drug of mecillinam (active metabolite)
- other metabolites: pivalic acid
- oral bioavailability 25-35%
- protein bindng < 25%
- urinary excretion , primarily as mecillinam (80% of dose)
Antimicrobial activity:
- Escherichia coli
- Proteus mirabilis &
- Staphylococcus saprophyticus
Adverse effects:
- nausea
- diarrhea
- carnitine defciency Test interference:
General
4th generation penicillin (extended-spectrum)
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Pivmecillinam
https://en.wikipedia.org/wiki/Pivmecillinam
- Remally J
FDA Approves New Antibiotic for Uncomplicated UTIs.
Medscape. April 26, 2024
https://www.medscape.com/viewarticle/fda-approves-new-antibiotic-uncomplicated-utis-2024a100087g
- FDA News Release. April 24, 2024
FDA Approves New Treatment for Uncomplicated Urinary Tract Infections.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Pivya (pivmecillinam) tablet for oral use.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216483s000lbl.pdf